Abstract
A synergistic increase in the cytotoxic effects of recombinant human tumor necrosis factor (rH-TNF) and anti-cancer drugs was demonstrated in vitro. The cytotoxicity of rH-TNF against L-M cells in combination with Mitomycin C (MMC), Adriamycin (ADM), Cytosine arabinoside (Ara-C), Actinomycin D (ACD), Daunomycin (DM), Cisplatin (CDDP), Vincristine (VCR), and 5-Fluorouracil (5FU), based on the concentration necessary for 50% inhibition of cell growth (IC50), was 4 to 347 times as high as that of rH-TNF alone. The results suggest that combination therapy including rH-TNF and anti-cancer drugs may be of value in the treatment of malignancy in human patients.
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Bleomycin / pharmacology
-
Cisplatin / pharmacology
-
Cytarabine / pharmacology
-
Cytotoxicity, Immunologic / drug effects*
-
Dactinomycin / pharmacology
-
Daunorubicin / pharmacology
-
Doxorubicin / pharmacology
-
Drug Synergism
-
Fluorouracil / pharmacology
-
Mitomycin
-
Mitomycins / pharmacology
-
Recombinant Proteins / pharmacology
-
Tumor Cells, Cultured / drug effects
-
Tumor Necrosis Factor-alpha / pharmacology*
-
Vincristine / pharmacology
Substances
-
Antineoplastic Agents
-
Mitomycins
-
Recombinant Proteins
-
Tumor Necrosis Factor-alpha
-
Cytarabine
-
Bleomycin
-
Dactinomycin
-
Mitomycin
-
Vincristine
-
Doxorubicin
-
Cisplatin
-
Fluorouracil
-
Daunorubicin